Improving lung cancer survival; time to move on

BMC Pulmonary Medicine

Joachim G Aerts¹  Bruno H Stricker²  Joost P Hegmans³  Marlies E Heuvers³ 

[1] Department of Respiratory Diseases and Tuberculosis, Amphia Hospital, Breda, The Netherlands;Department of Medical Informatics, Erasmus Medical University Center, Rotterdam, The Netherlands;Department of Respiratory Diseases and Tuberculosis, Erasmus Medical University Center, Rotterdam, The Netherlands

关键词: Immunotherapy;    Lung cancer screening;    Survival;    Lung cancer;   

Others  :  1136274
DOI  :  10.1186/1471-2466-12-77

 received in 2012-09-27, accepted in 2012-11-29,  发布年份 2012

【 摘 要 】

Background

During the past decades, numerous efforts have been made to decrease the death rate among lung cancer patients. Nonetheless, the improvement in long-term survival has been limited and lung cancer is still a devastating disease.

Discussion

With this article we would like to point out that survival of lung cancer could be strongly improved by controlling two pivotal prognostic factors: stage and treatment. This is corresponding with recent reports that show a decrease in lung cancer mortality by screening programs. In addition, modulation of the patient’s immune system by immunotherapy either as monotherapy or combined with conventional cancer treatments offers the prospect of tailoring treatments much more precisely and has also been shown to lead to a better response to treatment and overall survival of non-small cell lung cancer patients.

Summary

Since only small improvements in survival can be expected in advanced disease with the use of conventional therapies, more research should be focused on lung cancer screening programs and patient tailored immunotherapy with or without conventional therapies. If these approaches are clinically combined in a standard multidisciplinary policy we might be able to advance the survival of patients with lung cancer.

【 授权许可】

   
2012 Heuvers et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
• [2]Schiller JH, et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
• [3]Sugimura H, Yang P: Long-term survivorship in lung cancer: a review. Chest 2006, 129:1088-1097.
• [4]Goodgame B, et al.: Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol 2009, 4:1370-1374.
• [5]Goodgame B, et al.: A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer. Am J Clin Oncol 2008, 31:22-28.
• [6]Blanchon T, et al.: Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer 2007, 58:50-58.
• [7]van Klaveren RJ, et al.: Management of lung nodules detected by volume CT scanning. N Engl J Med 2009, 361:2221-2229.
• [8]International Early Lung Cancer Action Program: Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006, 355:1763-1771.
• [9]Vansteenkiste J, Dooms C, Mascaux C, Nackaerts K: Screening and early detection of lung cancer. Ann Oncol 2012, 23(Suppl 10):x320-x327.
• [10]National Lung Screening Trial Research, T: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
• [11]Heuvers ME, Stricker BH, Aerts JG: Generalizing lung-cancer screening results. N Engl J Med 2012, 366:192-193.
• [12]Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA: Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008, 86:2008-2016. discussion 2016–2008
• [13]Dahele M, Senan S: The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat 2011, 43:75-82.
• [14]Wisnivesky JP, et al.: Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study. BMJ 2011, 343:d4013.
• [15]Heuvers ME, et al.: History of tuberculosis as an independent prognostic factor for lung cancer survival. Lung Cancer 2012, 76:452-456.
• [16]Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL: 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011, 60:319-326.
• [17]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
• [18]Caux C, Zitvogel L: Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Target Oncol 2012, 7:1-2.
• [19]Zitvogel L, et al.: Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. Cancer Res 2010, 70:9538-9543.
• [20]Keyler DE, et al.: Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab Dispos 2005, 33:1056-1061.
• [21]Jadus MR, et al.: Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol 2012, 2012:160724.
• [22]Sharma P, Wagner K, Wolchok JD, Allison JP: Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011, 11:805-812.
• [23]Cornelissen R, et al.: New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol 2012, 2012:927240.
• [24]Cameron F, Whiteside G, Perry C: Ipilimumab: first global approval. Drugs 2011, 71:1093-1104.
• [25]Brahmer JR, et al.: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
• [26]Topalian SL, et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
• [27]Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P: Ipilimumab. Nat Rev Drug Discov 2011, 10:411-412.
• [28]Minchom A, Young K, Larkin J: Ipilimumab: showing survival benefit in metastatic melanoma. Future Oncol 2011, 7:1255-1264.
• [29]Dillman RO: Cancer immunotherapy. Cancer Biother Radiopharm 2011, 26:1-64.
• [30]Claret L, et al.: Simulations using a drug-disease modeling framework and phase ii data predict phase III survival outcome in first-line non-small-cell lung cancer. Clin Pharmacol Ther 2012, 92:631-634.
• [31]Manzoni M, et al.: Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 2010, 79:187-196.
• [32]Osada T, et al.: The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008, 57:1115-1124.
• [33]Winter H, et al.: Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis 2011, 3:105-114.
• [34]Um SJ, et al.: Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer 2010, 70:188-194.
• [35]Neninger Vinageras E, et al.: Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:1452-1458.
• [36]Barve M, et al.: Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008, 26:4418-4425.
• [37]Palmer M, et al.: Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cance. Clin Lung Cancer 2001, 3:49-57. discussion 58
• [38]Hegmans JP, et al.: Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010, 181:1383-1390.
• [39]Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR: Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57:365-372.
• [40]Perroud MW Jr, et al.: Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res 2011, 30:65. BioMed Central Full Text
• [41]Iliopoulou EG, et al.: A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010, 59:1781-1789.
• [42]Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308.